Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) is GW&K Investment Management LLC’s 7th Largest Position

GW&K Investment Management LLC decreased its holdings in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 0.5% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 1,387,462 shares of the biopharmaceutical company’s stock after selling 6,734 shares during the quarter. Intra-Cellular Therapies makes up 1.0% of GW&K Investment Management LLC’s investment portfolio, making the stock its 7th largest position. GW&K Investment Management LLC’s holdings in Intra-Cellular Therapies were worth $115,881,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently bought and sold shares of ITCI. True Wealth Design LLC acquired a new stake in Intra-Cellular Therapies during the 3rd quarter worth about $32,000. GAMMA Investing LLC lifted its position in shares of Intra-Cellular Therapies by 46.3% in the fourth quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company’s stock worth $63,000 after purchasing an additional 240 shares in the last quarter. Capital Performance Advisors LLP purchased a new stake in shares of Intra-Cellular Therapies in the third quarter worth approximately $74,000. Venturi Wealth Management LLC acquired a new stake in shares of Intra-Cellular Therapies during the fourth quarter worth approximately $96,000. Finally, Wilmington Savings Fund Society FSB purchased a new position in Intra-Cellular Therapies during the third quarter valued at approximately $97,000. 92.33% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ITCI has been the subject of a number of research analyst reports. Piper Sandler reiterated a “neutral” rating and issued a $132.00 target price (up previously from $107.00) on shares of Intra-Cellular Therapies in a research report on Tuesday, January 14th. Leerink Partnrs lowered Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a report on Monday, January 13th. Canaccord Genuity Group downgraded Intra-Cellular Therapies from a “buy” rating to a “hold” rating and boosted their target price for the company from $119.00 to $132.00 in a research note on Friday, January 31st. Baird R W lowered Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 13th. Finally, Cantor Fitzgerald upgraded Intra-Cellular Therapies from a “hold” rating to a “strong-buy” rating in a report on Tuesday, January 14th. Ten investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $106.08.

Intra-Cellular Therapies Stock Down 0.2 %

Shares of Intra-Cellular Therapies stock opened at $128.25 on Friday. Intra-Cellular Therapies, Inc. has a 12-month low of $63.30 and a 12-month high of $129.00. The stock has a 50 day moving average price of $112.80 and a two-hundred day moving average price of $90.87. The stock has a market capitalization of $13.64 billion, a P/E ratio of -147.41 and a beta of 0.72.

Intra-Cellular Therapies (NASDAQ:ITCI) last issued its quarterly earnings data on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. The firm had revenue of $199.22 million during the quarter, compared to analyst estimates of $205.08 million. Sell-side analysts anticipate that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current year.

Insiders Place Their Bets

In other Intra-Cellular Therapies news, CEO Sharon Mates sold 51,000 shares of Intra-Cellular Therapies stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $85.80, for a total value of $4,375,800.00. Following the transaction, the chief executive officer now directly owns 1,070,329 shares of the company’s stock, valued at $91,834,228.20. The trade was a 4.55 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 2.60% of the company’s stock.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.